Latest Pharma Insights
CMR Surgical Chose Agency Over Distribution To Keep Surgeons Close, CEO Says
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
Genmab’s Rina-S Succeeds In First Phase III Trial, Another Win For Late-Stage Portfolio
Genmab’s rinatabart sesutecan (Rina-S) reduced risk of disease progression by 71% and risk of death by 57% in platinum-resistant ovarian cancer (PROC) regardless of FR? expression, a competitive profile versus AbbVie’s first-in-class ADC Elahere.
Scrip - October 23, 2026
Genmab’s rinatabart sesutecan (Rina-S) reduced risk of disease progression by 71% and risk of death by 57% in platinum-resistant ovarian cancer (PROC) regardless of FR? expression, a competitive profile versus AbbVie’s first-in-class ADC Elahere.
Scrip - October 23, 2026
Tango Reports Positive Update On Vopimedostat Combo In Pancreatic Cancer
Tango’s PRMT5 inhibitor combined with Revolution Medicines’ Rasonque shows durability of effect in updated data from a Phase I/II study in metastatic pancreatic ductal adenocarcinoma.
Scrip - October 23, 2026
Tango’s PRMT5 inhibitor combined with Revolution Medicines’ Rasonque shows durability of effect in updated data from a Phase I/II study in metastatic pancreatic ductal adenocarcinoma.
Scrip - October 23, 2026
BMS Must Balance Patient Death With Promise Of Zola-Cel In MS
One patient died 44 days after receiving zolacabtagene autoleucel in the Phase I Breakfree-2 study in highly active relapsing multiple sclerosis. The primary endpoint was safety, but Bristol pointed to promising signs of efficacy.
Scrip - October 23, 2026
One patient died 44 days after receiving zolacabtagene autoleucel in the Phase I Breakfree-2 study in highly active relapsing multiple sclerosis. The primary endpoint was safety, but Bristol pointed to promising signs of efficacy.
Scrip - October 23, 2026
Roche Warns Germany That Time Is Running Out For A Pro-Pharma Strategy
The row between big pharma and Germany’s government has intensified, with many firms threatening to limit investment in the country.
Scrip - October 23, 2026
The row between big pharma and Germany’s government has intensified, with many firms threatening to limit investment in the country.
Scrip - October 23, 2026
ESMO 2026: BMS/SystImmune’s Iza-Bren Shows Solid PFS, Raises Questions On Safety
Efficacy among previously treated HR+/HER2- breast cancer patients looked in line with Merck/Kelun’s sac-TMT, but an analyst pointed to higher Grade 3+ TRAEs.
Scrip - October 23, 2026
Efficacy among previously treated HR+/HER2- breast cancer patients looked in line with Merck/Kelun’s sac-TMT, but an analyst pointed to higher Grade 3+ TRAEs.
Scrip - October 23, 2026
Vera To Get Commercialization Boost With Full Trutakna Data In IgAN
The biotech plans to seek full approval in the fourth quarter based on positive data from the Phase III ORIGIN 3 trial.
Scrip - October 23, 2026
The biotech plans to seek full approval in the fourth quarter based on positive data from the Phase III ORIGIN 3 trial.
Scrip - October 23, 2026
US Proposal To Restrict China Biotech Investment Leaves Licensing In A Gray Area
The US Treasury has issued a long-awaited proposal that would restrict US investment in biotech in China and other countries of concern, but whether licensing deals are covered would depend on their structure.
Scrip - October 23, 2026
The US Treasury has issued a long-awaited proposal that would restrict US investment in biotech in China and other countries of concern, but whether licensing deals are covered would depend on their structure.
Scrip - October 23, 2026
Biotechs Cash In On Priority Review Vouchers As Record Sales Signal Rising Demand
Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their highest since 2016.
Scrip - October 23, 2026
Disclosed priority review voucher sales have hit a record $1.78bn across nine deals this year, with average prices at their highest since 2016.
Scrip - October 23, 2026
Investors Bet That Star Can Repeat Past Successes With $200m Financing
Star Therapeutics, which sold subsidiary Vega to Incyte for $1.26bn up front this year, raised $200m in private financing to take its next round of novel biologics into the clinic.
Scrip - October 23, 2026
Star Therapeutics, which sold subsidiary Vega to Incyte for $1.26bn up front this year, raised $200m in private financing to take its next round of novel biologics into the clinic.
Scrip - October 23, 2026
Gilead Licenses Rival To J&J’s Icotyde In IBD Race Catch-Up
Deal Snapshot: Gilead is paying Pepstar/Peptidstar $1.3bn upfront for an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life in a bid to catch up with J&J’s Icotyde in inflammatory bowel disease.
Scrip - October 23, 2026
Deal Snapshot: Gilead is paying Pepstar/Peptidstar $1.3bn upfront for an oral macrocyclic peptide inhibitor of IL-23R with an extended half-life in a bid to catch up with J&J’s Icotyde in inflammatory bowel disease.
Scrip - October 23, 2026
CMR Surgical Chose Agency Over Distribution To Keep Surgeons Close, CEO Says
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
CMR Surgical CEO Massimiliano Colella said Stryker’s $400m investment is structured so CMR keeps training, marketing and surgeon relationships. He said the money speeds US and AI work and plans for a 2027 launch are on target; Stryker’s option to acquire CMR leaves independence an open question.
Medtech Insight - October 24, 2026
P&G To Bolster Thorne’s Growth Without Taking the Reins – CFO
P&G plans to help Thorne scale its business with supply chain, ingredient qualification and marketing capabilities while retaining the team and allowing it to lead the brand’s growth strategy.
HBW Insight - October 23, 2026
P&G plans to help Thorne scale its business with supply chain, ingredient qualification and marketing capabilities while retaining the team and allowing it to lead the brand’s growth strategy.
HBW Insight - October 23, 2026
L’Oréal CEO: GLP-1s Are Reshaping Skin Care Demand
L’Oréal CEO Nicolas Hieronimus says the company is responding to the GLP-1 weight loss trend with formulas that address the negative impact of the drugs on skin’s appearance, while also investing in formulas that address skin care needs before, during and after aesthetic treatments.
HBW Insight - October 23, 2026
L’Oréal CEO Nicolas Hieronimus says the company is responding to the GLP-1 weight loss trend with formulas that address the negative impact of the drugs on skin’s appearance, while also investing in formulas that address skin care needs before, during and after aesthetic treatments.
HBW Insight - October 23, 2026
Zydus Receives FDA Approval For First Generic Climara Pro
The US regulator has approved Zydus’s once-weekly transdermal hormone therapy patch for estradiol and levonorgestrel as a competitive generic therapy, triggering eligibility for a 180-day exclusivity period.
Generics Bulletin - October 23, 2026
The US regulator has approved Zydus’s once-weekly transdermal hormone therapy patch for estradiol and levonorgestrel as a competitive generic therapy, triggering eligibility for a 180-day exclusivity period.
Generics Bulletin - October 23, 2026
France’s Alma Urges Off-Patent Exemption From Latest Legislative Burdens
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
French off-patent industry association Alma has urged revisions to the country’s latest social security financing bill to avoid penalizing generics and biosimilars.
Generics Bulletin - October 23, 2026
Formycon Goes After Its First Niche-Buster Biosimilar With A Latin American Partner
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
Formycon has partnered with Uruguay-based Biocelys to develop an undisclosed “niche-buster” biosimilar, FYB286, targeting a rare disease. The deal is financed upfront by Santo Biosimilar, an entity controlled by Athos KG, which also controls Biocelys and is Formycon’s largest anchor shareholder.
Generics Bulletin - October 23, 2026
The Biological Case for Adopting New Approach Methodologies in Oncology
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026
The FDA’s oncology draft guidance supports using human-relevant NAMs to replace or augment animal toxicology studies, with biologics and ADCs best positioned because their targeted behavior makes safety predictable.
In Vivo - October 23, 2026